.jpg)
STAT+: A preview of Neurocrine’s muscarinic drug readout
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Category: biotechnology
A potential rival for Wegovy and Zepbound enters the fray
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Sponsored genetic testing programs are under fire, further complicating life for people with rare diseases
It takes years for most people with a rare disease to learn what is ailing…
Merck lays off workers amid rough pharma job market
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Sage suffers pipeline setback with failure of drug to treat essential tremor
Sage Therapeutics said Wednesday that an experimental pill failed to quell involuntary muscle shaking in…
STAT+: Pfizer gene therapy reduced hemophilia bleeds, but questions remain
Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for…
Contradictory coverage decisions in North Carolina
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
Four health care and biotech updates to stay on top of this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novo, Lilly shares sink due to concerns over competition
Hellloooooo. Today, we discuss the FDA’s lack of engagement with critics of MDMA for PTSD…
STAT+: Novartis not ready to admit a $3 billion mistake
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
The biotech news stories you need to know today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Q&A: The new CEO of biotech’s top trade group on China, vaccines, and Trump
WASHINGTON — BIO’s new CEO John Crowley is making changes. He’s pivoting the biotechnology industry’s…
STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world
Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the…
STAT+: Gilead’s chief medical officer to leave as R&D efforts stall
Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker…
It’s happy hour (for now) for Alnylam
Good morning and happy Wednesday. Today we’re talking about insulin, pharma’s ties with politicians, and…
Sen. Menendez’s conviction may cost pharma a key ally in Congress
A New York jury on Tuesday found Sen. Bob Menendez guilty on 16 counts for…
STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund
Cardurion Pharmaceuticals, a startup that launched seven years ago with shelved cardiovascular drug candidates from…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Vertex sues U.S. government over access to fertility support services for Casgevy patients
One of the makers of the Casgevy — the world’s first CRISPR-based medicine — filed a lawsuit…
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Element Biosciences raises another massive round
Want to stay on top of the science and politics driving biotech today? Sign up to get…
CAR-T therapy’s complications, as well as its benefits, become clearer in ‘flurry’ of cancer studies
Researchers were perplexed when the Food and Drug Administration announced it was investigating whether CAR-T…
Listen: Biotech layoffs, founder-focused VC, & a big pharma exit
Why are pharmaceutical companies cutting more staff than cash-strapped biotechs? And who will Pfizer scout…
Can you get satiety with GLP-1s without the nausea?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
uniQure shares soar on Huntington’s data
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: VC Flagship Pioneering raises $3.6 billion in new funds
Flagship Pioneering, one of the largest firms investing in and creating new biotech companies, said…
STAT+: Biopharma layoffs are leaving the industry’s scientists reeling — and in search of scarce opportunities
After getting laid off from Bristol Myers Squibb last December, Jennifer Ariazi is trying her…
STAT+: Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down
Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael…
Lilly’s obesity drug looks more potent than Novo’s in observational study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A faster, simpler, cheaper cancer cell therapy is about to be tested in humans
In a long-awaited study, patients in Australia will soon receive an IV infusion designed to…
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Eli Lilly to acquire Morphic for $3.2 billion
Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for…
Constructing an atlas of human biology in space: Q&A with Chris Mason
After several delays, the highly anticipated first commercial spacewalk is set to launch later this…
GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership
GSK and CureVac have restructured an ongoing partnership that gives the British pharma giant control…
STAT+: What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: FDA approves Eli Lilly’s early Alzheimer’s treatment
Eli Lilly’s early Alzhiemer’s treatment was approved by the Food and Drug Administration on Tuesday,…
STAT+: Report shows U.S. biotechs are wary of Chinese partnerships due to looming BIOSECURE Act
A looming anti-China biotechnology bill has spooked U.S. life sciences companies, according to a new…
STAT+: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes
The unilateral decision by Peter Marks, a top official at the Food and Drug Administration,…
STAT+: The biotech scorecard for the third quarter: 19 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry
The Food and Drug Administration’s power to make important regulatory decisions is in question after…
STAT+: Cassava Sciences collaborator charged with defrauding NIH in grants supporting its Alzheimer’s drug
A Cassava Sciences collaborator and paid consultant has been indicted by a federal grand jury…
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA rejects Rocket Pharmaceuticals’ gene therapy for ultra-rare condition, another setback for field
Rocket Pharmaceuticals said Friday that the Food and Drug Administration rejected its gene therapy for…
Opinion: To secure the U.S.’s biotech supply chain, pay attention to domestic companies
Scientific breakthroughs will enable a future of personalized drug discovery, where precision medicine makes it…
Listen: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy? And what health…
STAT+: Trying to outrun her prion disease, researcher creates powerful epigenetic editor in mice
Sonia Vallabh always thought genome editing wouldn’t be an option. It was such an obvious…
Exclusive: European VC Forbion hires Dyne CEO, expands into US
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Journal retracts study tied to Micronoma’s effort to create blood cancer test
Nature retracted a high-profile paper that served as part of the scientific groundwork for Micronoma,…
Intellia says its CRISPR-based therapy can be redosed
Want to stay on top of the science and politics driving biotech today? Sign up to get…